Introduction
============

Atherosclerosis is a degenerative inflammatory vascular disease (Ross, [@b78]). It is the primary underlying cause of CVD and by causing myocardial infarction and stroke; it has become the leading cause of morbidity and mortality in the Western world today (WHO, [@b102]; Go *et al*., [@b41]). The economic revolution in Southeast Asia and the accelerating urbanization of China and India, combined with the prevalence of traditional CVD risk factors in particular, is expected to increase CVD incidence dramatically by 2020 (Celermajer *et al*., [@b18]). Our knowledge of the cellular and molecular mechanisms causing and aggravating atherosclerosis has increased substantially in the last several years, however, we still face serious challenges trying to discriminate the relatively benign stable atherosclerotic plaque from the high-risk (vulnerable) plaque in a clinical setting (Fleg *et al*., [@b37]; Joshi *et al*., [@b49]). The use of ultrasound allow some qualitative evaluation of carotid plaques; however, selection criteria for surgical intervention for high-risk plaques of the internal carotid artery; carotid endarterectomy (CEA) remains largely based on the degree of carotid stenosis (Hobson *et al*., [@b44]). What is needed is a clinical tool for identification of the vulnerable plaque so that CEA is only performed on patients standing to benefit from the procedure, thereby reducing the numbers needed to treat which is currently about six to one (Chaturvedi *et al*., [@b19]). Molecular imaging has the potential as a tool for identification of the vulnerable plaque; allowing for risk stratification and individualized preventive intervention, as well as enabling clinicians to monitor the effect of medical therapy.

Molecular imaging is a technology enabling visualization of the molecular interaction and distribution of a probe (hereon referred to as a tracer) with its target or pathway in an intact biological system, i.e. *in vivo*. Existing molecular imaging modalities comprise contrast-enhanced ultrasound, optical imaging, magnetic resonance imaging (MRI), single photon emission computed tomography (SPECT) and positron emission tomography (PET). It is the scope of this review to present current advances and potential future applications of PET for *in vivo* atherosclerotic disease management in human patients.

Pathogenesis of atherosclerosis
===============================

Atherosclerosis is a systemic artery vessel wall disease characterized by inflammation (Ross, [@b78]; Hansson & Libby, [@b43]). Originally, plaque development was subdivided into four major stages, whereas the modern perception is that of a more seamless transition over time. Initiation of plaque development is a result of endothelial dysfunction with a decrease in nitric oxide (NO) bioavailability, oxidative excess and subsequent inflammation (Endemann & Schiffrin, [@b31]; Vita, [@b96]). A pro-inflammatory state results and expression of vascular cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1) by endothelial cells (ECs) initiate white blood cell recruitment (Endemann & Schiffrin, [@b31]). Monocytes then infiltrate the artery intima where they differentiate into macrophages and start to engulf lipids such as oxidized low-density lipoprotein (oxLDL), primarily via scavenger receptors class A, B and D, resulting in macrophage transformation into foam cells and development of a fatty streak (Libby, [@b57]; Rahaman *et al*., [@b73]; Ashraf & Gupta, [@b6]). With increased complexity of the lesion, foam cells become overwhelmed and form a necrotic core. Chemokines such as C-C motif ligand-2 (CCL-2) and monocyte chemoattractant protein-1 (MCP-1) secreted from ECs and vascular smooth muscle cells (VSMCs) stimulate a continuous influx of white blood cells into the lesion (Hansson & Libby, [@b43]). Foam cell remnants and necrotic debris then make up a highly thrombogenic lipid rich core and VSMCs start migrating into the lesion to form the basis of a fibrous cap by modification of the extracellular matrix. A hypoxic microenvironment stimulate the formation of microvessels from the *vasa vasorum* forming a highly immature plaque vasculature facilitating further white blood cell recruitment and haemorrhagic episodes due to microvessel immaturity (Virmani *et al*., [@b95]). The fulminant plaque may then protrude into the arterial lumen increasing the risk of organ ischemic events distal to the plaque, see Fig.[2](#fig02){ref-type="fig"}. An acellular plaque with a large lipid core separated from the blood by a thin fibrous cap may rupture and lead to myocardial infarction or stroke and is therefore by definition a vulnerable plaque (Finn *et al*., [@b36]).

Positron emission tomography
============================

The PET is a medical imaging technique based on the detection of radioactive decay from positron emitting radionuclides (β^+^ decay). The radionuclide coupled tracer is usually administered intravenously when clinically used. The tracer is designed to target a specific biochemical or pharmacological interaction *in vivo*, which can then be visualized in 3D following computer reconstruction, *qua* the associated radioactive decay which is recorded by the PET scanner (Cherry & Dahlbom, [@b20]). By drawing regions of interest (ROIs) on reconstructed imaging data the quantity of tracer uptake can be calculated for that region. The first *in vivo* detection of annihilation radiation (see below) as we know it today was performed in two dogs in 1975 using a prototype positron emission tomograph (Phelps *et al*., [@b70]; Ter-Pogossian *et al*., [@b91]). The positron is essentially a positive electron (e^+^) ejected from the isotope nucleus with a kinetic energy in the range of a few mega-electron volt (MeV). As the positron travels through tissue, the kinetic energy is deposited by multiple direction changing interactions with tissue electrons prior to uniting with an electron (e^−^) to undergo annihilation whereby the mass of the positron and an electron is converted into electromagnetic energy. The reaction produces two photons with the energy of 511 kilo-electron volt (keV) emitted back to back.

The PET scanner detects annihilation photons that escape the body. The detection system is configured so that opposite detectors is coupled to form a coincidence circuit in which the back to back emitted photons can be detected within a specified time window. The volume between the detector pairs where the coincidence detection takes place is called the line of response (LOR) and is made up by voxels each representing a 3D volume in space. Detection of thousands and thousands of these events at different angles and radial offsets followed by extensive computer analysis allows reconstruction of 3D images (Phelps *et al*., [@b70]; Cherry & Dahlbom, [@b20]).

A particular challenge to clinical PET imaging is the imaging of small structures as that of the vessel wall in atherosclerotic disease. The inherent 'blurring' of PET images is due to the finite spatial resolution of the system of which two fundamental limitations are of paramount importance; acollinearity and positron range (Cherry & Dahlbom, [@b20]; Moses, [@b58]). Of these factors only positron range can be affected and only by either selecting an alternate parent isotope or by using a powerful magnetic field to affect positron trajectory thereby decreasing positron range. Both options present great challenges in either chemical synthesis effort, or high equipment cost and are therefore considered impractical (Moses, [@b58]). However, the recent emergence of the first combined clinical PET/MRI scanners may prove an exception to at least part of this consensus (Schlemmer *et al*., [@b83]). Another important consideration when imaging small structures is the partial volume effect which describes how a small lesion with high tracer uptake in a low tracer background will result in the signal being spread out. This spill-out of signal from the lesion is also true for signal spilling back in from the background making the partial volume effect very hard to predict and compensate. In a small lesion this interprets to a lesser maximal value of lesion tracer uptake than the actual maximum value tracer uptake as well as an apparent larger lesion size (Cherry & Dahlbom, [@b20]; Soret *et al*., [@b86]). It is important to understand that partial volume effect does not cause signal loss, but that it does cause signal displacement (Soret *et al*., [@b86]).

Annihilation photons are likely to experience either attenuation or scatter events predominantly by Compton interactions in the tissue and the result is the removal of the annihilation photon from the original LOR. Recent advances have led to the implementation of analytical models correcting for single scatter events, by single scatter scaling (SSS), which is a reasonable approximation of total scatter when compared with modelling of events of second or higher order of scatter (Polycarpou *et al*., [@b72]). With the introduction of the first clinical hybrid PET/CT scanners (Beyer *et al*., [@b11]), attenuation correction can be performed by direct measurement using the CT modality to calculate a map of attenuation coefficients, of the patient, which is subsequently used to correct PET emission data (Burger *et al*., [@b17]).

Although the limited spatial resolution of PET is a major disadvantage when imaging small structures such as the vessel wall this can be complemented by co-registration with either CT or MRI, whereby detailed anatomical information can be combined with the PET imaging modality to locate precisely the anatomical distribution of tracer uptake and ease the drawing of ROIs (Beyer *et al*., [@b11]; Von Schulthess *et al*., [@b97]; Schlemmer *et al*., [@b83]). With acollinearity and positron range being fundamental limitations, the best intrinsic spatial resolution of full body clinical PET scanners achievable is just below 3 mm at the centre field of view (Moses, [@b58]); however, using algorithms to modify the point spread function (PSF) of the scanner a resolution as good as 2 mm is practically achievable (Panin *et al*., [@b65]; Levin *et al*., [@b55]).

PET tracers in atherosclerosis
==============================

When considering the bulk of PET tracer use there are basically two types of tracers clinically used; 2-\[^18^F\]-fluoro-2-deoxy-D-glucose (^18^F-FDG) and the more recently introduced non-^18^F-FDG tracers. At the Department of Nuclear Medicine, Clinical Physiology & PET, Rigshospitalet in Copenhagen approximately 88% of all PET imaging in the years 2004--2012 was performed using ^18^F-FDG (internal communication). Being a university hospital, Rigshospitalet has a high research activity and a comparable conventional PET facility would perform approximately 95--100% of all PET imaging using ^18^F-FDG. Therefore, we will discuss the research of atherosclerosis according to these two tracer types. Important milestones and novel research areas of each type are summarized in Tables[1](#tbl1){ref-type="table"} and [2](#tbl2){ref-type="table"} respectively.

###### 

Milestones; *In vivo* ^18^F-FDG-uptake in human atherosclerosis using PET

  Target                                                     Modality                                                             Study type                                                                       Notes                                                                                   Reference
  ---------------------------------------------------------- -------------------------------------------------------------------- -------------------------------------------------------------------------------- --------------------------------------------------------------------------------------- ----------------------------
                                                             Standalone PET                                                       Retrospective study of cancer patients                                           First report on ^18^F-FDG-uptake in arteries                                            Yun *et al*. ([@b105])
                                                             Sequential PET/CT with retrospective imaging alignment               Prospective study (first)                                                        First study specifically of atherosclerosis in humans using PET/CT                      Rudd *et al*. ([@b79])
                                                             Hybrid PET/CT                                                        Retrospective study of cancer patients                                           First report using true hybrid PET/CT to study atherosclerosis                          Tatsumi *et al*. ([@b89])
  MΦ (CD68), immunochemistry                                 Sequential PET/CT and PET/MRI with retrospective imaging alignment   Prospective and correlational to cell type (MΦ)                                  First noninvasive study to assess inflammation by MΦ infiltration quantitatively        Tawakol *et al*. ([@b90])
  Drug intervention, Simvastatin                             Sequential PET/CT with retrospective imaging alignment               Prospective study of patients screened for cancer                                First interventional study, attenuation of ^18^F-FDG-uptake found                       Tahara *et al*. ([@b87])
  PET reproducibility in atherosclerosis                     Hybrid PET/CT                                                        Prospective study of patients with vascular disease                              Very good interscan variability for the internal carotid artery: 0·90; CI: 0·68--0·97   Rudd *et al*. ([@b80])
  CD68, cathepsin K, MMP-9 and IL-18 gene expression         Hybrid PET/CT                                                        Prospective study of patients receiving surgery (CEA) for atherosclerosis        First study of the molecular pathology of atherosclerosis                               Graebe *et al*. ([@b42])
  Angiogenesis; gene expression of α~V~β~3~, CD34 and VEGF   Hybrid PET/CT                                                        Prospective study of patients receiving surgery (CEA) for atherosclerosis        First study of angiogenesis using ^18^F-FDG                                             Pedersen *et al*. ([@b68])
  Hypoxia; gene expression of HIF-1α                         Hybrid PET/CT                                                        Prospective study of patients receiving surgery (CEA) for atherosclerosis        First study of hypoxia using ^18^F-FDG                                                  Pedersen *et al*. ([@b69])
  Comparison of PET/MRI to PET/CT                            Hybrid PET/MRI                                                       Feasibility of simulta-neous PET/MRI for ^18^F-FDG imaging of carotid arteries   First PET/MRI in carotid arteries                                                       Ripa *et al*. ([@b76])

α~V~β~3~, integrin dimer consisting of integrin α~V~ and integrin β~3~; CD34, cluster of differentiation 34; CD68, cluster of differentiation 68 -- a macrophage marker; CEA, carotid endarterectomy; CI, confidence interval (95%); CT, computed tomography; ^18^F-FDG, 2-\[^18^F\]-fluoro-2-deoxy-D-glucose; HIF-1α, hypoxia inducible factor-1α; IL-18, interleukin 18; MΦ, macrophages; MMP-9, matrix metalloproteinase-9; MRI, magnetic resonance imaging; PET, positron emission tomography; VEGF, vascular endothelial growth factor.

###### 

Novel PET tracers for human use: Potential in atherosclerosis risk stratification?

  Target                                 Modality         Study type                                   Notes                                                                                                       Reference
  -------------------------------------- ---------------- -------------------------------------------- ----------------------------------------------------------------------------------------------------------- -----------------------------
  Active calcification using ^18^F-NaF   Hybrid PET/CT    Retrospective study of cancer patients       First report and feasibility study of atherosclerosis in different arterial vascular beds using ^18^F-NaF   Derlin *et al*. ([@b25])
  MΦ activity (SSTR~2~)                  Hybrid PET/CT    Retrospective study of cancer patients       First study of MΦ activity in atherosclerosis using the tracer ^68^Ga-DOTATATE                              Rominger *et al*. ([@b77])
  MΦ activity (SSTR~2~) and glycolysis   Hybrid PET/CT    Retrospective study of cancer patients       First comparison of ^18^F-FDG and ^68^Ga-DOTATATE in atherosclerotic disease                                Li *et al*. ([@b56])
  Hypoxia                                Standalone PET   Prospective study of cancer patients         First study of hypoxia using ^18^F-FMISO uptake in cancer patients                                          Valk *et al*. ([@b92])
  Hypoxia                                Standalone PET   Prospective study of cancer patients         First study of hypoxia using ^62^Cu-ATSM uptake in cancer patients                                          Takahashi *et al*. ([@b88])
  Angiogenesis (α~V~β~3~)                Standalone PET   Biodistribution and pharmacokinetics study   First study of angiogenesis using ^18^F-Galacto-RGD in cancer patients                                      Beer *et al*. ([@b8])

α~V~β~3~, integrin receptor dimer alpha~V~beta~3~; CT, computed tomography; ^62^Cu-ATSM, ^62^Cu-diacetyl-bis(*N*^4^methyl-thiosemicarbazone); ^18^F-FDG, 2-\[^18^F\]-fluoro-2-deoxy-D-glucose; ^18^F-FMISO, ^18^F-fluoromisonidazole; ^18^F-NaF, ^18^F-sodium fluoride;^68^Ga-DOTATATE, ^68^Ga-\[1,4,7,10-tetraazacyclododecane-*N*,*N′*,*N″*,*N‴*-tetraaceticacid\]-ᴅ-Phe^1^,Tyr^3^-octreotate; MΦ, macrophages; PET, positron emission tomography; SSTR~2~, somatostatin receptor subtype 2.

^18^F-FDG
=========

^18^F-FDG is the workhorse among the PET tracers. It is a glucose analogue with the positron emitter ^18^F (*t*~½~ = 110 min) substituted for the OH-group in the second position of the carbon backbone of D-glucose. A reproducible synthesis method of ^18^F-FDG was first reported in the late 1970s (Gallagher *et al*., [@b39]; Ido *et al*., [@b46]); however, as early as 1976, the first two human volunteers at the University of Pennsylvania were administered ^18^F-FDG. ^18^F-FDG enables visualization of tissues with an elevated level of glycolysis by a process of metabolic trapping (Gallagher *et al*., [@b40]), Fig.[1](#fig01){ref-type="fig"}.

![Metabolic trapping of ^18^F-FDG: The inflammatory active cells take up ^18^F-FDG via GLUT1/3. Phosphorylation by hexokinase in the cytosol yields ^18^F-FDG-6-Phosphate which cannot be further processed by the metabolic machinery of the cell, effectively trapping ^18^F-FDG. The slim arrow depicts the reciprocal reaction which does occur but is negligible. ^18^F-FDG, 2-\[^18^F\]-fluoro-2-deoxy-D-glucose.](cpf0034-0413-f12105-f1){#fig01}

In 1977 the first ^18^F-FDG scan was reported using a human subject. The images were recorded of the cerebrum, however, a non-PET scanner was used (Reivich *et al*., [@b74]). The discovery that a high metabolic demand for glucose was a key requirement of cancer cells was discovered as early as the 1920s by Otto Warburg and was aptly referred to as the Warburg effect ever since (Warburg *et al*., [@b98]). Today the heritage of Otto Warburg is carried on by ^18^F-FDG as the main PET tracer of choice in standalone PET and hybrid PET/CT imaging in cancer patient management (Von Schulthess *et al*., [@b97]; Czernin *et al*., [@b21]). It has come to the attention of clinicians and researchers in turn that accumulation of ^18^F-FDG is linked not only to cancer, but to benign and more generalized pathology as well. Accordingly, ^18^F-FDG uptake is expected to be noticeable during the course of atherogenesis in which inflammatory activity and thereby glycolysis is high (Vallabhajosula & Fuster, [@b93]; Shreve *et al*., [@b84]).

In 2001 this awareness led to the first retrospective report of ^18^F-FDG uptake in the large arteries of cancer patients (Yun *et al*., [@b105]) and this was soon followed by the first prospective study designed to evaluate atherosclerotic disease using ^18^F-FDG PET/CT in man (Rudd *et al*., [@b79]). The latter study also used an elegant approach with tritiated deoxyglucose (an *in vitro* analogue of ^18^F-FDG) and autoradiography to demonstrate that activity accumulated in macrophage rich areas of atherosclerotic plaques. This made it plausible that macrophages were responsible for the ^18^F-FDG-uptake seen by PET/CT *in vivo*, see Fig.[2](#fig02){ref-type="fig"}, an observation very much in line with the emerging consensus that atherosclerosis is an inflammatory disease (Ross, [@b78]). As a natural consequence of this work, the first study to seek to quantitate lesion macrophages by immunohistochemistry (% CD68 staining) to *in vivo* ^18^F-FDG uptake; target to background ratio (TBR) found a good correlation between the two (*r* = 0·70; *P*\<0·0001) when comparing sections of internal carotid lesions to corresponding imaging data obtained prior to CEA (Tawakol *et al*., [@b90]). An even better correlation was found when comparing mean ^18^F-FDG uptake to mean lesion (% CD68 staining) inflammation (*r* = 0·85; *P*\<0·0001) (Tawakol *et al*., [@b90]).

![Atherosclerosis and molecular imaging: The vulnerable atherosclerotic plaque protrudes into the vessel lumen as a result of progressive inflammation of the vessel wall intima. Monocytes are continuously recruited from the blood and into the intima where they differentiate to macrophages and become foam cells due to lipid ingestion. Eventually, foam cells are overcome and become apoptotic amassing to a lipid rich necrotic core which is covered by a thin fibrous cap. Expansion of the intima leads to hypoxia which drives angiogenesis whereby new blood vessels sprout from the vasa vasorum in the vessel wall media. PET-tracers are depicted in blue and arrows point to their respective molecular targets. Integrin α~V~β~3~, integrin receptor dimer alpha~V~beta~3~; ^18^F-FDG, 2-\[^18^F\]-fluoro-2-deoxy-D-glucose; ^18^F-FMISO, ^18^F-fluoromisonidazole; ^18^F-NaF, ^18^F-sodium fluoride; ^68^Ga-DOTATATE, ^68^Ga-\[1,4,7,10-tetraazacyclododecane-*N*,*N′*,*N″*,*N‴*-tetraaceticacid\]-ᴅ-Phe^1^,Tyr^3^-octreotate; GLUT, glucose transporter; PET, positron emission tomography; SSTR~2~, somatostatin receptor subtype 2.](cpf0034-0413-f12105-f2){#fig02}

This was later corroborated in two studies using patient subsets from the prior study to correlate% CD68 staining with TBR (Fifer *et al*., [@b34]; Figueroa *et al*., [@b35]). The earlier of those two studies made the comparison indirectly and was a cross-sectional study of retrospective nature. Although highly significant and comparable correlations were found in the three studies, the question of timing from the ^18^F-FDG PET scan to CEA could be raised as patients went for up to a month before having their plaque removed. That question was addressed when it was determined that ^18^F-FDG PET scans performed 2 weeks apart on the same cohort of patients exhibited an interscan variability (0·90, 95% confidence interval; CI: 0·68--0·97), inter-observer agreement (0·97; CI: 0·89--0·99) and finally intra-observer agreement (0·95; CI: 0·89--0·99) for the carotid arteries (Rudd *et al*., [@b80]). The latter study was followed by a set of recommendations for ^18^F-FDG PET/CT imaging in human subjects with atherosclerosis and a demonstration of even better performance in a study with a comparative design, but including more different vascular beds (Rudd *et al*., [@b81]). The low numbers of patients included in these two studies is a limitation (11 and 19 patients, respectively) and two retrospective cancer studies have quite clearly demonstrated that long term ^18^F-FDG-uptake in major arterial segments change in a large proportion of re-evaluated patients over the course of several months (Ben-Haim *et al*., [@b10]; Wasselius *et al*., [@b99]). However, if time from the initial PET scan to CEA can be reduced to match the former studies (Rudd *et al*., [@b80], [@b81]) or perhaps even shorter, the validity of the correlation between the imaging modality and the subsequent tissue analysis should, theoretically, pose no problem.

The thickness of the vessel walls of the large arteries are on the edge of the resolution of the best standalone PET systems today. Therefore, the emergence of true hybrid PET/CT scanners (Beyer *et al*., [@b11]) represented a leap in molecular imaging, which was quickly evaluated to establish its potential in human atherosclerosis research (Tatsumi *et al*., [@b89]). The first prospectively designed study to use optimal post-injection scan times (3 h) in combination with almost immediate plaque recovery came from our group in 2009. We demonstrated a correlation between molecular pathology (gene expression) and ^18^F-FDG-uptake using hybrid PET/CT with a focus on molecular markers of inflammation and vulnerability (Graebe *et al*., [@b42]). In that study CEA was performed the day after the ^18^F-FDG PET/CT scan and the correlation between ^18^F-FDG-uptake and gene expression of the macrophage marker CD68 (*r* = 0·71; *P* = 0·02 and *n* = 10) was comparable with the first immunohistochemical findings on a per-patient level (Tawakol *et al*., [@b90]). Further investigations which included more patients reproduced the findings regarding CD68 (*r* = 0·38; *P*\<0·0001 and *n* = 17) using a slice-by-slice approach of each lesion for comparison with ^18^F-FDG uptake (Pedersen *et al*., [@b66]).

Atherogenesis leads to remodelling and thickening of the vessel wall intima which may precipitate hypoxia and lead to angiogenesis as a compensatory measure (Ribatti *et al*., [@b75]), Fig.[2](#fig02){ref-type="fig"}. Evidence of hypoxia was first produced in an elegant non-imaging study (Sluimer *et al*., [@b85]) and this was corroborated by an *in vitro* study using an ^18^F-FDG-analog to produce evidence that hypoxia, not inflammation, increased glucose-uptake by macrophages *per se* (Folco *et al*., [@b38]). The first study directly linking the marker of hypoxia; hypoxia inducible factor-1α (HIF-1α) to ^18^F-FDG-uptake *in vivo* was recently published by our group (Pedersen *et al*., [@b69]). So far a single study has explored the association between neoangiogenesis, by gene expression of the integrin dimer α~V~β~3~ and ^18^F-FDG-uptake in man, however, no correlation was found (Pedersen *et al*., [@b67]). Finally, a brand new study introduced demonstrated the feasibility of simultaneous hybrid PET/MRI of the carotid arteries using ^18^F-FDG (Ripa *et al*., [@b76]).

The promise of ^18^F-FDG PET as a method to monitor medical intervention in atherosclerosis was explored in the first interventional study using the HMG-CoA reductase inhibitor simvastatin (in a dynamic dose regime; 5--20 mg day^−1^) in addition to dietary management compared with a purely dietary management group (Tahara *et al*., [@b87]). That study found that simvastatin alone attenuated plaque ^18^F-FDG-uptake in the thoracic aorta and/or carotid arteries, and that this correlated with high-density lipoprotein cholesterol (HDL-C) *elevation*. A more recent study using atorvastatin in low (5 mg day^−1^) and high (20 mg day^−1^) dose found that a reduction in ^18^F-FDG-uptake in the ascending aorta and the femoral artery was associated with low-density lipoprotein cholesterol (LDL-C) *reduction* in both groups, however, only the high dose of atorvastatin led to significant attenuation of the ^18^F-FDG signal when compared with the baseline scan (Ishii *et al*., [@b47]). Furthermore, no difference in ^18^F-FDG-uptake between the treatment groups was found, and therefore any dose-response relationship could not be elucidated. The latest statin-based interventional study used atorvastatin (40 mg day^−1^) to treat previously statin free (1 year) subjects with confirmed significant atherosclerosis of at least one vascular territory (Wu *et al*., [@b103]). Seven different arterial segments were measured to assess ^18^F-FDG-uptake and again a significant reduction of ^18^F-FDG-uptake was found with treatment. In agreement with the earlier study (Ishii *et al*., [@b47]) circulating LDL-C was lowered but in contrast to the first interventional study (Tahara *et al*., [@b87]) HDL-C was now found to be significantly reduced (Wu *et al*., [@b103]). No change, however, was seen in the coronary artery calcium (CAC) score or various adipose fat volume measurements. Earlier findings suggested that statin treatment reduce ^18^F-FDG active plaques and with it calcified late-stage plaque burden which support the notion that ^18^F-FDG accumulation represents a transient inflammatory state culminating in a calcified non-reversible endpoint (Wasselius *et al*., [@b100]).

Very recently ^18^F-FDG PET has been introduced in clinical drug trials with TBR measurements as primary endpoint of an index vessel selected on the basis of the highest average maximum TBR before and after treatment with losmapimod (a p38 mitogen-activated protein kinase inhibitor) as add-on therapy to statins. Significant attenuation of ^18^F-FDG uptake in active sites of inflammation was found, however, not upon evaluation of the vessels using an all-segment TBR approach (Elkhawad *et al*., [@b30]). The dal-PLAQUE study used dalcetrapib (a cholesteryl ester transfer protein modulator) as add-on therapy to LDL lowering therapy. It was found that an increase in HDL-C was associated with a decrease in TBR of most-diseased-segments of artery as well as attenuation of total vessel area; however, that effect was only recorded in the carotid arteries, not the index vessels (Fayad *et al*., [@b33]). Active sites of inflammation are the most cell rich sites of atherosclerotic plaques with macrophages and vascular smooth muscle cells (VSMC) making up the bulk of the cells (Jonasson *et al*., [@b48]), we therefore suggest that any effect measured by ^18^F-FDG PET would most likely be associated with such characteristics.

With careful consideration of sample size; what is cumulatively learned by these interventional studies is that statin treatment reduces ^18^F-FDG-uptake in atherosclerotic plaques whether it be reported by the mean/maximal standardized uptake value (SUV~mean~, SUV~max~) (Tahara *et al*., [@b87]; Wasselius *et al*., [@b100]) or the target to background (TBR) model of ^18^F-FDG accumulation (Ishii *et al*., [@b47]; Wu *et al*., [@b103]). Interventional studies using novel drugs demonstrate that ^18^F-FDG PET can be used to assess drug effects on plaques in a clinical setting (Fayad *et al*., [@b33]; Elkhawad *et al*., [@b30]). The case is made for large cohort event-driven prospective studies to further elucidate the anti-inflammatory effect of statins as well as novel drugs for treatment of atherosclerosis and the eligibility of ^18^F-FDG-PET as a surrogate endpoint to monitor such non-invasive therapy.

Non-FDG PET-tracers in atherosclerosis imaging
==============================================

From the diversity of studies presented, it becomes apparent that for its excellent properties ^18^F-FDG has one major drawback; its lack of specificity. As all living cells can utilize glucose we need a tracer that specifically targets the cell-mediated key molecular processes associated with the vulnerable atherosclerotic plaque. Most prominent of these targets are macrophage infiltration, calcification, apoptosis, hypoxia and neoangiogenesis of the intima/media (Ross, [@b78]; Tawakol *et al*., [@b90]; Ribatti *et al*., [@b75]; Sluimer *et al*., [@b85]; Dweck *et al*., [@b28]).

^18^F-NaF
---------

One feature in atherogenesis is localized 'spotty' calcification which is thought to promote plaque vulnerability (Motoyama *et al*., [@b59]). The tracer sodium \[^18^F\]-fluoride ^18^F-NaF was originally developed and introduced for bone scintigraphy in 1962 (Blau *et al*., [@b13]) but has re-emerged recently with the introduction of PET, see Fig.[2](#fig02){ref-type="fig"}. ^18^F-NaF is deposited by chemisorption onto hydroxyapatite (Czernin *et al*., [@b22]) and that infers hydroxyapatite presence within the atherosclerotic lesion itself. Mineralization of the artery wall can be initiated by VSMCs responding to stress by oxidized lipids (Watson *et al*., [@b101]; Yan *et al*., [@b104]) as well as inflammation and macrophage accumulation which coincide with osteogenic activity (Aikawa *et al*., [@b3]). It is beyond the scope of this review to extensively cover the background of osteogenesis in atherosclerosis; which has excellently been discussed previously (Doherty *et al*., [@b27]; Demer & Tintut, [@b24]). Using hybrid PET/CT and a retrospective approach it was recently described how ^18^F-NaF accumulated in atheroma of the aorta, iliac, femoral and carotid arteries (Derlin *et al*., [@b25], [@b26]); however, also that coincidental ^18^F-NaF and ^18^F-FDG uptake (14 of 215 lesions; 6·5%) is rare (Derlin *et al*., [@b26]). This could be due to different lesion properties, e.g. inflammation versus calcification, although it cannot be ruled out that time between ^18^F-NaF and ^18^F-FDG scans may have influenced this result (Derlin *et al*., [@b26]). A recent study scanned the patients 1 day apart and found a modest correlation (*r*^2^* *=* *0·171, *P*\<0·001) between ^18^F-NaF and ^18^F-FDG uptake in calcific aortic valvular disease (Dweck *et al*., [@b29]). Although this seems to support the initial observation of poorly overlapping uptake patterns of ^18^F-NaF and ^18^F-FDG, the studies are not directly comparable and data are not identically presented. Contrary to ^18^F-FDG, ^18^F-NaF specifically targets bone and bone turnover and we have no reason to believe that uptake of these two tracers should perfectly coincide. This lack of tracer uptake co-localization earlier led investigators to hypothesize that it was a reflection of differences in disease stage (Derlin *et al*., [@b26]).

In another study ^18^F-NaF uptake was found to be associated with major adverse cardiovascular events as well as an increase in Framingham risk prediction score (Dweck *et al*., [@b28]). More importantly 41% of patients with CAC score \>1000 had no significant ^18^F-NaF uptake and that adds weight to the hypothesis that only metabolically active calcific plaques are imaged by ^18^F-NaF (Dweck *et al*., [@b28]), i.e. late plaques developing an increasingly vulnerable phenotype. However, *bona fide* histological validation of this hypothesis is still lacking. With careful consideration of the research we find it justified to assume that ^18^F-NaF PET scan adds independent information to what is learned from an ^18^F-FDG PET scan alone. A very recent publication produced evidence that plaque calcification followed focal inflammation in the same arterial location as detected by ^18^F-FDG PET at an earlier time point (Abdelbaky *et al*., [@b1]). Based on the newest data, further assessment of ^18^F-NaF PET in atherosclerosis should certainly be warranted, however, the first prospective studies are still to be seen.

^68 ^Ga-DOTATATE
----------------

The inflammatory active atherosclerotic lesion is continuously infiltrated by blood monocytes that differentiate into macrophages which eventually become lipid loaded foam cells (Ross, [@b78]). The association between ^18^F-FDG uptake and macrophages has been substantiated earlier (Rudd *et al*., [@b79]; Tawakol *et al*., [@b90]), however, by targeting the somatostatin receptor subtype 2 (SSTR~2~) expressed by macrophages (Dalm *et al*., [@b23]; Armani *et al*., [@b5]), it should be possible to obtain higher specificity than what ^18^F-FDG PET offers (Fig.[2](#fig02){ref-type="fig"}) and potentially reveal all states in plaque development where macrophages are abundant. The somatostatin receptor ligand ^68 ^Ga-\[1,4,7,10-tetraazacyclododecane-*N*,*N′*,*N″*,*N‴*-tetraaceticacid\]-ᴅ-Phe^1^,Tyr^3^-octreotate (DOTATATE) has high affinity for SSTR~2~ (Breeman *et al*., [@b14]) and can be used in combination with ^18^F-FDG for imaging and evaluation of neuroendocrine tumors by clinical PET (Kayani *et al*., [@b50]). The potential for imaging macrophages in atherosclerosis was first explored in a study comparing ^68 ^Ga-DOTATATE uptake in the coronary arteries with presence of calcified plaques and risk factors for cardiovascular disease (Rominger *et al*., [@b77]). Male sex and prior vascular events correlated with ^68 ^Ga-DOTATATE uptake (TBR) and a correlation with calcified plaques was also found (*R *=* *0·34; *P*\<0·01). However, in 14 of 25 (56%) of cases no colocalization with calcified plaques and ^68 ^Ga-DOTATATE uptake was found, suggesting not all calcified plaques had a significant macrophage population (Rominger *et al*., [@b77]). The fact that less than half of the calcified plaques exhibited ^68 ^Ga-DOTATATE accumulation could suggest that end-stage or 'stable' calcified plaques without active inflammation may account for the bulk of the ^68 ^Ga-DOTATATE negative calcified plaques. It would be interesting to see what could be learned from comparison between ^68 ^Ga-DOTATATE and ^18^F-NaF scans in this context. The second of the two existing studies using ^68 ^Ga-DOTATATE so far, compared ^68 ^Ga-DOTATATE to ^18^F-FDG uptake in a retrospective study of cancer patients (Li *et al*., [@b56]). The earlier findings was corroborated when ^68 ^Ga-DOTATATE was found to correlate with calcified plaques (*R *=* *0·52; *P*\<0·05), however, less than half (43%) of vascular sites with the highest focal ^68 ^Ga-DOTATATE uptake was also ^18^F-FDG positive and conversely only 28% of the sites with the highest focal ^18^F-FDG uptake sites co-localized with ^68 ^Ga-DOTATATE (Li *et al*., [@b56]). Clearly ^68 ^Ga-DOTATATE and ^18^F-FDG are not equally distributed. As pointed out by the researchers themselves the tracer kinetics of ^68 ^Ga-DOTATATE and ^18^F-FDG could be an issue as saturation kinetics could be feature of SSTR~2~ receptor imaging which was not the case when using ^18^F-FDG (Li *et al*., [@b56]). Another study found that proliferating human umbilical vein endothelial cells expressed SSTR subtypes 2 and 5 *in vitro* suggesting a possible role in angiogenesis (Adams *et al*., [@b2]). We know angiogenesis is an important feature of the advanced plaque and therefore we cannot rule out that ^68 ^Ga-DOTATATE may detect more than macrophages in atherosclerosis imaging. Considering these facts, the number of included patients (*n* = 70 and *n* = 16, respectively) and the retrospective nature of these two studies, care must be taken when interpreting the results. However, the stronger correlation of ^68 ^Ga-DOTATATE than ^18^F-FDG with cardiovascular risk factors encourages further investigations of the distribution differences between these two tracers. Histological validation of ^68 ^Ga-DOTATATE uptake in the atherosclerotic plaque is a logical next step as is the elucidation of the biological significance of tracer distribution for the vulnerable plaque.

Future PET-tracer targets
=========================

As mentioned earlier perhaps the three most obvious molecular processes to target in plaque imaging is hypoxia, neoangiogenesis and apoptosis. First, hypoxia of the atherosclerotic arterial wall has been found to colocalize with accumulation of foam cells and macrophages *in vivo* in an experimental rabbit model as well as in humans (Bjornheden *et al*., [@b12]; Sluimer *et al*., [@b85]). Evidence that hypoxia increase macrophage ^18^F-FDG uptake has been observed (Folco *et al*., [@b38]) suggests that imaging hypoxia itself may offer an alternate approach, one that is already pursued in cancer imaging (Valk *et al*., [@b92]; Takahashi *et al*., [@b88]). Second, the vitronectin receptor α~V~β~3~ is associated with neoangiogenesis and known to be expressed in atherosclerotic arteries (Hoshiga *et al*., [@b45]). It is recognized by and binds to the arginine-glycine-aspartic acid (RGD) motif. So far human imaging studies performed with a tracer based on RGD-ligands are scarce (Beer *et al*., [@b8], [@b9]) and preclinical testing has shown promise as well (Oxboel *et al*., [@b64]; Pohle *et al*., [@b71]). Third, phosphatidylserine (PS) a cell membrane phospholipid, is externalized to the outer cell membrane during apoptosis, a key feature of the vulnerable atherosclerotic plaque (Koopman *et al*., [@b53]; Kolodgie *et al*., [@b52]). Thus targeting PS is a definite possibility and has been performed as early as 2003, however, not using PET (Van de Wiele *et al*., [@b94]). With these data in mind the first clinical PET study of atherosclerosis focusing on these key molecular processes (Fig.[2](#fig02){ref-type="fig"}) is expected in the not too distant future.

Indications for introduction of atherosclerosis PET imaging
===========================================================

A significant number of patients are known to suffer acute ischemic events in the absence of significant (≤50%) artery stenosis (Aldrovandi *et al*., [@b4]; Kovacic & Fuster, [@b54]). Indications for CEA are based on ipsilateral symptomatic ischemic events distal to a carotid plaque of ≥70% degree stenosis as determined by ultrasound. Although some qualitative information can be evaluated using modern ultrasound systems, selection of patients for CEA remains largely based on the degree of stenosis (Hobson *et al*., [@b44]). In our eyes this is an inadequate approach considering the patient cohort with non-significant carotid artery stenosis who experience acute ischemic stroke. What is needed is plaque characterization whereby plaque vulnerability can be evaluated. PET could potentially be the tool that, together with ultrasound, improves patient selection criteria thereby reducing the need to treat ratio. Recent work has indicated that CEA of symptomatic low grade carotid stenosis is safe and thus better selection criteria sensitivity are warranted and should be pursued (Ballotta *et al*., [@b7]). PET is a powerful technique with unsurpassed sensitivity and should be considered as a tool for achieving this goal.

Challenges in atherosclerosis PET imaging
=========================================

Recently, the concept of the 'vulnerable patient' has been introduced (Naghavi *et al*., [@b61],[@b62]). First, to find a regional vulnerable internal carotid artery plaque using PET does not take into account the global status of the patient being evaluated for CEA and therefore co-morbidities characterizing the vulnerable patient could be missed in such a setup. Second, although arterial ^18^F-FDG uptake is highly correlated between different large artery vascular territories (Rudd *et al*., [@b82]), evaluation of ^18^F-FDG uptake in large versus small arteries such as the coronary and cerebral arteries is largely hampered by the significant myocardial and cerebral ^18^F-FDG uptake. On the other hand, CT assessment of plaque burden (calcium score) in the aorta and coronary arteries revealed a strong correlation between the two (Kim *et al*., [@b51]). This could be an indication of what should be further investigated using PET in a similar setup if technically feasible. Bearing this in mind, atherosclerosis is a systemic disease and vascular territories should be evaluated separately when clinically indicated to ensure optimal treatment. A third challenge is cost: PET scans are not inexpensive and therefore PET has been subjected to economic evaluations from early clinical implementation and proved cost effective in the management of an array of cancers (Buck *et al*., [@b16]). Accordingly, if effective in identifying vulnerable carotid plaques, the cost of an unnecessary CEA surgery clearly outperforms the cost of a PET scan several-fold not to forget the unnecessary discomfort and added risk inflicted upon the patient. Finally, a clinical ^18^F-FDG PET/CT scan subjects the patient to ionizing radiation. In a typical whole body scanning procedure the absorbed dose from the tracer is less than half the dose received by that from the CT modality alone (Brix *et al*., [@b15]). The unmatched sensitivity, the fact that the technique is non-invasive and quantifiable, is considered to outweigh the drawbacks when imaging human atherosclerosis (Owen *et al*., [@b63]). The focus of this review has been the potential role of PET in atherosclerotic disease management. Hybrid PET/CT and PET/MRI provide complementary information to the PET modality; however, it is beyond the scope of this review to venture further into the specific advantages of each alternative imaging modality. However, some key characteristics of different important imaging modalities in plaque characterization have been summarized in Table[3](#tbl3){ref-type="table"}.

###### 

Comparison of non-invasive imaging modalities for atherosclerotic plaque characterization

                                       PET     MRI   CT      US
  ------------------------------------ ------- ----- ------- -------
  Plaque 'activity' (metabolism)       +++     \+    **−**   \+
  Plaque composition                   **−**   +++   \+      ++
  IMT -- vessel wall characteristics   **−**   ++    **−**   +++
  Calcification                        **−**   \+    +++     ++
  Sensitivity                          +++     ++    **−**   **−**

+++, very good performance; ++, intermediate performance: **+,** limited performance; **−**, not applicable; CT, computed tomography; IMT, intima-media thickness; MRI, magnetic resonance imaging; PET, positron emission tomography; US, ultrasound.

Concluding remarks
==================

It is perhaps not immediately intuitive, but many molecular targets are shared by cancer and atherosclerotic disease. No finer example of this was the way atherosclerosis imaging research started; with the observation that some cancer patients had an increased ^18^F-FDG uptake in the large arteries (Yun *et al*., [@b105]). From that, as well as the other examples reviewed, it is likely that future tracer 'firsts' in atherosclerosis imaging will continue to be of retrospective nature with a foundation in cancer research. It follows that by rationally and systematically re-evaluating 'old' tracers in retrospective studies before putting them to use in a new context, the achievements in PET-based atherosclerosis research brings hope for a better understanding of this disease on a molecular level. From what is seen in this review it is obvious that there is a continuous drive in the imaging community towards testing of existing tracers in new contexts. As important as this, there is focus on the development of new tracers for molecular imaging of atherosclerosis using PET. What knowledge is gained from the existing tracers should be applied for further development of new tracers followed by comprehensive prospective preclinical testing in animal models. Finally, promising new tracers should be introduced in small populations paving the way for full clinical implementation. In atherosclerosis research, the aim is the development of a safe clinical tool for non-invasive *in vivo* risk stratification of patients with symptomatic atherosclerotic disease. With apoptosis and new angiogenesis tracers close to clinical introduction the future for molecular imaging is rich in perspectives. The goal should be to learn as much as possible whereas improving and ideally substituting current implementations to benefit future patients in need of stratification for vascular surgery.

On a final note the first true event-driven prospective studies in atherosclerosis using molecular imaging were initiated in 2008/2009; the high-risk plaque initiative (Falk *et al*., [@b32]) and the associated BioImage study (Muntendam *et al*., [@b60]). As we are waiting for these results we should commit ourselves to continuously apply new as well as established tracers in new contexts in clinical research working towards an even brighter future for patients with atherosclerosis as well as for molecular imaging itself.
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